moxifloxacin has been researched along with Disease Models, Animal in 115 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (2.61) | 18.2507 |
| 2000's | 54 (46.96) | 29.6817 |
| 2010's | 51 (44.35) | 24.3611 |
| 2020's | 7 (6.09) | 2.80 |
| Authors | Studies |
|---|---|
| Cottagnoud, M; Cottagnoud, P; Schaffner, T; Stucki, A; Winkelmann, V | 1 |
| Giamarellou, H; Kyroudi, A; Papalois, A; Pefanis, A; Skiadas, I; Triantafyllidi, H; Tsaganos, T | 1 |
| Adams, DA; Donskey, CJ; Riggs, MM | 1 |
| Almeida, D; Bishai, WR; Grosset, J; Nuermberger, E; Tyagi, S | 1 |
| Daw-Garza, A; Lozano-Garza, HG; Ocampo-Candiani, J; Rocha, NC; Said-Fernández, S; Vera-Cabrera, L; Waksman de Torres, N; Welsh, O | 1 |
| Dussurget, O; Fontanet, A; Grayo, S; Join-Lambert, O; Le Monnier, A; Lott-Desroches, MC; Respaud, R; Singlas, E | 1 |
| Arhin, FF; Caron, L; Delorme, D; Dietrich, E; Fadhil, I; Ferreira, SS; Houghton, TJ; Kang, T; Laquerre, K; Lehoux, D; Liu, J; Moeck, G; Ostiguy, V; Parr, TR; Poirier, H; Rafai Far, A; Sarmiento, I; Tanaka, KS; Viens, F | 1 |
| Cavazos-Rocha, N; Chacon-Moreno, BE; de la Luz Salazar-Cavazos, M; Garza-Lozano, HG; Ocampo-Candiani, J; Said-Fernandez, S; Vera-Cabrera, L; Welsh, O | 1 |
| Angulo-Barturen, I; Beltrán, M; Cáceres, N; Cardona, PJ; García, JI; García-Bustos, JF; Rullas, J | 1 |
| Ambady, A; Butler, S; Chatterji, M; Cooper, CB; Humnabadkar, V; Iyer, PS; Jena, LK; Manjunatha, MR; McLaughlin, RE; Mdluli, K; Nanduri, R; Narayanan, S; Panda, M; Panduga, V; Prabhakar, KR; Ravishankar, S; Reddy, J; Sadler, C; Sambandamurthy, VK; Saralaya, R; Shandil, RK; Sharma, S; Shirude, PS; Srivastava, A; Suresh, RS; Whiteaker, J | 1 |
| Alfonso, S; Ballell, L; Barros Aguirre, D; Bates, RH; Biava, M; Cocozza, M; Consalvi, S; De Logu, A; Fernandez-Menendez, R; Poce, G; Venditti, G; Vistoli, G | 1 |
| Bhagavathula, M; Bhatt, K; Deretic, VP; Ellner, JJ; Salgame, P; Timmins, GS; Verma, S | 1 |
| Carr, W; Converse, PJ; Dartois, V; Dooley, KE; Garcia, A; Kurbatova, E; Nuermberger, EL; Stout, JE; Tasneen, R; Vernon, AA; Zimmerman, MD | 1 |
| Artero, R; Boido, M; Januel, C; Konieczny, P; Mamchaoui, K; Martinat, C; Menduti, G | 1 |
| Dohgu, S; Inada, K; Koga, M; Yamada, A; Yamauchi, A | 1 |
| Alves, P; Bozukova, D; Coimbra, P; Colaço, R; Filipe, HP; Galante, R; Gil, MH; Guiomar, AJ; Mamalis, N; Masson, M; Mata, J; Oliveira, AS; Pimenta, A; Saramago, B; Serro, AP; Topete, A; Vieira, AP; Werner, L | 1 |
| Artero, R; Konieczny, P | 1 |
| Cai, BY; Chu, NH; Du, YD; Gao, S; Ge, QP; Guo, R; Han, XQ; Huang, XR; Jing, W; Nie, LH; Nie, WJ; Shang, YY; Shi, WH; Teng, TL; Wang, J; Wang, QF; Xie, ZY; Zhou, WQ | 1 |
| Giacani, L; Haynes, AM; Mayans, MV; Mitjà, O; Nieto, C; Pérez-Mañá, C; Quintó, L; Romeis, E; Ubals, M | 1 |
| Aubry, A; Bernard, C; Chauffour, A; Chavanet, P; El Helali, N; Jarlier, V; Maitre, T; Petitjean, G; Reibel, F; Veziris, N | 1 |
| Choreftaki, T; Galanopoulos, I; Giamarellos-Bourboulis, EJ; Giannitsioti, E; Kanellakopoulou, K; Papalois, A; Poultsides, LA; Soranoglou, V | 1 |
| Converse, PJ; Li, SY; Mdluli, K; Nuermberger, EL; Soni, H; Tasneen, R; Tyagi, S | 1 |
| Ando, K; Cao, X; Izumi-Nakaseko, H; Matsukura, S; Naito, AT; Nakamura, Y; Sugiyama, A; Wada, T | 1 |
| Kim, JY; Lee, SJ; Nam, KY | 1 |
| Albaayit, SFA; Ghafil, JA; Hafiz, MH; Radhi, SN; Radif, HM; Zgair, AK | 1 |
| Arriens, S; Ford, L; Hoerauf, A; Hübner, MP; Klarmann-Schulz, U; Koschel, M; Martin, C; Pfarr, KM; Specht, S; Sternberg, S; Taylor, MJ | 1 |
| Bax, HI; de Knegt, GJ; de Steenwinkel, JEM; Mourik, BC; Simonsson, USH; Svensson, RJ; Verbon, A | 1 |
| Coates, AR; Davies, GR; Gillespie, SH; Hu, Y; Liu, Y; Pertinez, H | 1 |
| Kim, KH; Kim, MJ; Kim, S; Le, VH; Lee, JA; Lee, JH; Lee, S; Park, JH; Tchah, H | 1 |
| Dhaliwal, DK; Kowalski, RP; Mammen, A; Romanowski, EG; Shanks, RMQ | 1 |
| Chang, H; Im, SH; Jang, MH; Jang, WH; Kim, CJ; Kim, KH; Kim, MJ; Kim, YM; Myung, SJ; Park, A; Wang, T; Yang, BG | 1 |
| Brandt, CT; Figueiredo Filho, CA; Maior, GIS; Marquis, VWPB; Mascena, GV; Moura, LCRV; Paz, ARD | 1 |
| Chojnacki, M; Dunman, PM; Philbrick, A; Reed, JN; Tomaras, A; Wozniak, RAF; Wucher, B | 1 |
| Clemens, DL; Dillon, BJ; Horwitz, MA; Lee, BY; Li, Z; Plamthottam, S; Tullius, MV; Wang, R; Yu, CJ; Zink, JI | 1 |
| Arrey, F; Gengenbacher, M; Kaiser, P; Kaufmann, SHE; Krishnamoorthy, G; Kuhlmann, S; Löwe, D; Lozza, L; Maertzdorf, J; Moura-Alves, P; Nouailles, G; Skrahina, A; Skrahina, T | 1 |
| Ahmad, Z; Grosset, JH; Minkowski, A; Nuermberger, EL; Peloquin, CA; Tyagi, S | 1 |
| Aktas, Z; Arikan, S; Dinçel, A; Hasanreisoglu, B; Ozdek, S | 1 |
| Amoabeng, O; Mdluli, KE; Minkowski, A; Nuermberger, EL; Tasneen, R; Upton, AM; Williams, K | 1 |
| Berg, J; Gruber, AD; Gutbier, B; Hellwig, K; Hippenstiel, S; Hocke, AC; Kershaw, O; Mayer, K; Müller-Redetzky, HC; Neudecker, J; Opitz, B; Rückert, J; Suttorp, N; Wienhold, SM; Witzenrath, M | 1 |
| Ambati, BK; Archer, B; Cho, YK; Das, SK; Uehara, H | 1 |
| Fukuda, M; Sasaki, H | 1 |
| Akyar, I; Celik, E; Cosar, CB; Gonen, T; Ince, U; Kucuk, M; Serteser, M; Tokat, F | 1 |
| Gupta, P; Gupta, UD; Khuller, GK; Kumar, V; Tanushree, P; Vemuri, N | 1 |
| Aubry, A; Bernard, C; Brossier, F; Chauffour, A; Robert, J; Veziris, N | 1 |
| Jeong, H; Kim, KH; Kim, MJ; Lee, JH; Lee, S | 1 |
| Chew, J; Hunter, B; Jensen, M; Kleinmann, G; Mamalis, N; Meyer, JJ; Moshirfar, M; Stevens, S; Werner, L | 1 |
| Almeida, D; Grosset, JH; Nuermberger, EL; Rosenthal, IM; Zhang, M | 1 |
| Donta, I; Galani, L; Giamarellou, H; Iliopoulos, D; Karayiannakos, P; Pefanis, A; Sakka, V; Skiadas, I; Triantafyllidi, H | 1 |
| Marquart, ME; Moore, QC; Norcross, EW; Sanders, ME; Shafiee, A | 2 |
| Andries, K; Guillemont, J; Jarlier, V; Koul, A; Lounis, N; Veziris, N | 1 |
| Anisimov, BI; Ryzhko, IV; Trishina, AV; Tsuraeva, RI | 1 |
| Akyürek, N; Deren, YT; Hasanreisoğlu, B; Kalkanci, A; Ozdek, S | 1 |
| Liu, YN; Wang, D; Wang, Y | 1 |
| Hesje, CK; Marquart, ME; Moore, Q; Norcross, EW; Sanders, ME; Sanfilippo, CM; Shafiee, A | 1 |
| Andries, K; Gevers, T; Lounis, N | 1 |
| Cakici, H; Guven, M; Kocoglu, E; Ozturan, KE; Yucel, I | 1 |
| Hesje, CK; Marquart, ME; Moore, QC; Norcross, EW; Sanders, ME; Sanfilippo, CM; Shafiee, A | 1 |
| Balzli, CL; Caballero, AR; O'Callaghan, RJ; Tang, A; Weeks, AC | 1 |
| King, LB; Marquart, ME; Norcross, EW; Sanders, ME; Taylor, SD; Tolo, I; Tullos, NA | 1 |
| Kim, JY; Kim, SY | 1 |
| DeGroote, MA; Gilliland, JC; Kendall, LV; Lenaerts, AJ; Magden, ER; Weiner, CM | 1 |
| Beekman, JD; de Boer, TP; Duker, G; Houtman, MJ; Jonsson, MK; Nalos, L; Peschar, M; Rook, MB; Sartipy, P; Thomsen, MB; van der Heyden, MA; van der Nagel, R; van Veen, TA; Varkevisser, R; Vos, MA | 1 |
| Celen, MK; Ozekinci, S; Sakalar, YB | 1 |
| Barry, CE; Dartois, V; Goh, A; Kern, S; Kjellsson, MC; Low, KM; Pillai, G; Via, LE; Weiner, D | 1 |
| Bishai, WR; Davis, SL; Harper, J; Jain, SK; Kramnik, I; Nuermberger, EL; Pomper, MG; Skerry, C; Tasneen, R; Weir, M | 1 |
| Chen, X; Guo, X; Shi, G; Wang, H; Wang, S; Zhang, X | 1 |
| Hao, L; He, S; Li, H; Zhu, S | 1 |
| Fu, L; Jin, H; Li, P; Lu, Y; Mdluli, K; Upton, AM; Wang, B; Xu, J; Zhao, W; Zheng, M; Zhu, H | 1 |
| Kawasaki, S; Mito, T; Ohashi, Y; Suzuki, T; Tasaka, Y; Uda, T; Uno, T | 1 |
| Akova, YA; Asena, L; Bozkurt, A; Demiralay, E; Goktaş, MT; Karabay, G; Yaşar, U | 1 |
| Fridman, E; Lev, A; Levi, I; Rubinstein, E; Strahilevitz, J | 1 |
| Bermudez, LE; Inderlied, CB; Kolonoski, P; Petrofsky, M; Wu, M; Young, LS | 1 |
| Bishai, WR; Chaisson, RE; Grosset, JH; Nuermberger, EL; O'Brien, RJ; Tyagi, S; Vernon, AN; Yoshimatsu, T | 1 |
| Braun, J; Dirnagl, U; Halle, E; Megow, D; Meisel, A; Meisel, C; Prass, K; Victorov, I; Volk, HD; Wolf, T | 1 |
| Chiba, K; Hagiwara, T; Hashimoto, K; Sugiyama, A; Takahashi, S; Takasuna, K | 1 |
| Chuah, SK; Gollapudi, S; Thadepalli, H | 1 |
| Gordon, YJ; Kowalski, RP; Mah, FS; Romanowski, EG; Yates, KA | 2 |
| Bishai, WR; Chaisson, RE; Grosset, JH; Nuermberger, EL; O'Brien, RJ; Rosenthal, I; Tyagi, S; Vernon, AA; Williams, K; Yoshimatsu, T | 1 |
| Bast, DJ; Bell, D; Chen, X; de Azavedo, JC; Dresser, L; Low, DE; Mandell, LA; Saskin, R; Yue, M | 1 |
| Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D | 1 |
| Cetinkaya, Z; Ermis, SS; Kiyici, H; Ozturk, F | 1 |
| Dashieva, DG; Elistratova, NA; Mikhaĭlova, LP; Mozhokina, GN; Sokolova, GB | 1 |
| Charles, PE; Chavanet, P; Croisier, D; Etienne, M; Lequeu, C; Piroth, L; Portier, H; Pugin, J | 1 |
| Bishai, WR; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, K | 1 |
| Bishai, WR; Grosset, JH; Nuermberger, E; Rosenthal, I; Tyagi, S; Williams, KN | 1 |
| Bradley, JA; Cass, JD; Chen, X; Dahm, CM; Engwall, MJ; Kadyszewski, E; Sun, Z; Zhou, J | 1 |
| Böttcher, T; Brocke, VV; Djukic, M; Eiffert, H; Gerber, J; Nau, R; Wellmer, A | 1 |
| Athanasopoulos, G; Donta, I; Galani, L; Giamarellou, H; Iliopoulos, D; Pefanis, A; Sakka, V | 1 |
| Brooks, TJ; Lever, MS; Piercy, T; Steward, J | 1 |
| Bolduc, DL; Brook, I; Camp-Hyde, TD; Elliott, TB; Foriska, MA; Germana, A; Giraldo, DE; Jackson, WE; Ledney, GD; Shoemaker, MO; Thakar, JH | 1 |
| Cupp, GA; Dajcs, JJ; Schlech, BA; Stroman, DW | 1 |
| Caballero, AR; Dajcs, JJ; Johnston, KH; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA | 1 |
| Alou, L; del Carmen Ponte, M; Gracia, M; Huelves, L; López-Casla, MT; Martínez-Marín, C; Prieto, J; Sevillano, D; Soriano, F | 1 |
| Blair, C; Kirtsreesakul, V; Luxameechanporn, T; Naclerio, RM; Thompson, K | 1 |
| Garweg, JG; Kodjikian, L | 1 |
| Bayar, B; Bozkurt, A; Dinçel, A; Duman, S; Kaya, E; Oflu, Y; Yağci, R; Yağci, S | 1 |
| Breithardt, G; Cakir, Y; Eckardt, L; Engelen, MA; Haverkamp, W; Hilker, E; Milberg, P; Mönnig, G; Osada, N; Ramtin, S; Stypmann, J | 1 |
| Barequet, IS; Belkin, M; Habot-Wilner, Z; Lavinsky, F; Rosner, M; Ziv, H | 1 |
| Hiddemen, JW; McCartney, MD; Rice, RL; Shepard, AR; Wax, MB; Williams, KK | 1 |
| Bishai, WR; Chaisson, RE; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, KN; Zhang, M | 1 |
| Chang, ST; Chen, CC; Cheng, KC; Chuang, YC; Huang, HC; Shieh, CC; Yu, WL | 1 |
| Arda, B; Calik, S; Pullukcu, H; Sipahi, H; Sipahi, OR; Tasbakan, M; Turhan, T; Ulusoy, S; Yamazhan, T | 1 |
| Balzli, CL; Caballero, AR; Huang, B; McCormick, CC; O'Callaghan, RJ; Smith, E; Tang, A; Wigington, L | 1 |
| Almeida, D; Grosset, JH; Nuermberger, E; Rosenthal, I; Tasneen, R; Tyagi, S; Williams, KN | 1 |
| Akache, F; Daniel, SJ; Duval, M; Sahmkow, S | 1 |
| Cakir, N; Kuruuzum, Z; Sezak, N; Yuce, A | 1 |
| Brück, W; Chen, V; Dalhoff, A; Kohlsdorfer, C; Nau, R; Schmidt, H; Schneider, O; Stuertz, K; Trostdorf, F | 1 |
| Bergogne-Bérézin, E | 1 |
| Eiffert, H; Mäder, M; Nau, R; Schmidt, H; Stuertz, K; Trostdorf, F | 1 |
| Bui, KQ; Mattoes, H; McNabb, J; Nicolau, DP; Nightingale, CH; Quintiliani, R; Xuan, D; Zhong, M | 1 |
| Grosset, J; Ji, B | 1 |
| Dalhoff, A; Krasemann, C; Tillotson, G; Wegener, S | 1 |
| Fabian, I; Halperin, D; Kletter, Y; Nagler, A; Shalit, I; Vasserman, E; Waldman, D | 1 |
3 review(s) available for moxifloxacin and Disease Models, Animal
| Article | Year |
|---|---|
[R207910 (TMC207): a new antibiotic for the treatment of tuberculosis].
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitors; Ethionamide; Fluoroquinolones; Humans; Mice; Moxifloxacin; Mycobacterium tuberculosis; Placebos; Quinolines; Tuberculosis | 2010 |
In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone.
Topics: Administration, Topical; Animals; Aza Compounds; Bacteria; Corneal Ulcer; Disease Models, Animal; Drug Resistance, Microbial; Eye Infections, Bacterial; Fluoroquinolones; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Moxifloxacin; Ophthalmic Solutions; Quinolines | 2005 |
Penicillin-resistant streptococcus pneumoniae: review of moxifloxacin activity.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Clinical Trials as Topic; Disease Models, Animal; Fluoroquinolones; Humans; Moxifloxacin; Penicillin Resistance; Penicillins; Quinolines; Streptococcus pneumoniae | 2001 |
112 other study(ies) available for moxifloxacin and Disease Models, Animal
| Article | Year |
|---|---|
Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H]choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall.
Topics: Animals; Anti-Bacterial Agents; Bacteriolysis; Ceftriaxone; Cell Wall; Cerebrospinal Fluid; Choline; Daptomycin; Disease Models, Animal; Humans; Meningitis, Pneumococcal; Microbial Sensitivity Tests; Penicillin Resistance; Rabbits; Streptococcus pneumoniae; Treatment Outcome; Tritium | 2007 |
Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
Topics: Adjuvants, Immunologic; Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Aortic Valve; Aza Compounds; Dexamethasone; Disease Models, Animal; Echocardiography; Endocarditis, Bacterial; Fluoroquinolones; Humans; Methicillin; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome | 2007 |
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
Topics: Anaerobiosis; Animals; Anti-Infective Agents; Bacterial Toxins; Cecum; Clostridioides difficile; Disease Models, Animal; Disease Outbreaks; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Fluoroquinolones; Humans; Mice; Microbial Sensitivity Tests | 2007 |
In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Lung; Mice; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Quinolines; Tuberculosis | 2007 |
In vivo therapeutic effect of gatifloxacin on BALB/c mice infected with Nocardia brasiliensis.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Disease Models, Animal; Female; Fluoroquinolones; Gatifloxacin; Humans; Linezolid; Mice; Mice, Inbred BALB C; Nocardia; Nocardia Infections; Oxazolidinones; Treatment Outcome | 2008 |
Rapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Brain; Brain Diseases; Central Nervous System Bacterial Infections; Disease Models, Animal; Fluoroquinolones; Listeria monocytogenes; Listeriosis; Mice; Moxifloxacin; Quinolines; Time Factors; Treatment Outcome | 2008 |
Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis.
Topics: Animals; Disease Models, Animal; Esters; Female; Fluoroquinolones; Humans; Molecular Structure; Organophosphonates; Osteomyelitis; Prodrugs; Rats | 2008 |
Efficacy of ciprofloxacin and moxifloxacin against Nocardia brasiliensis in vitro and in an experimental model of actinomycetoma in BALB/c mice.
Topics: Animals; Aza Compounds; Ciprofloxacin; Disease Models, Animal; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycetoma; Nocardia; Quinolines | 2009 |
Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.
Topics: Acetamides; Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Drug Discovery; Ethambutol; Fluoroquinolones; Immunocompetence; Inhalation Exposure; Isoniazid; Linezolid; Mice; Mice, Inbred C57BL; Moxifloxacin; Oxazolidinones; Pyrazinamide; Quinolines; Reproducibility of Results; Rifampin; Tuberculosis, Pulmonary | 2010 |
Lead optimization of 1,4-azaindoles as antimycobacterial agents.
Topics: Alcohol Oxidoreductases; Animals; Antitubercular Agents; Bacterial Proteins; Cyclic Nucleotide Phosphodiesterases, Type 6; Disease Models, Animal; Humans; Indoles; Mice; Mycobacterium tuberculosis; Oxidoreductases; Rats; Structure-Activity Relationship | 2014 |
In vivo potent BM635 analogue with improved drug-like properties.
Topics: Animals; Antitubercular Agents; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Hep G2 Cells; Humans; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Pyrroles; Structure-Activity Relationship; Tuberculosis | 2018 |
Rapamycin modulates pulmonary pathology in a murine model of Mycobacterium tuberculosis infection.
Topics: Animals; B-Lymphocytes; Cell Aggregation; Disease Models, Animal; Female; Lung; Mice; Moxifloxacin; Mycobacterium tuberculosis; Necrosis; Neutrophil Infiltration; Polymethacrylic Acids; Sirolimus; Tuberculosis | 2021 |
Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Isoniazid; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifabutin; Tuberculosis | 2022 |
Moxifloxacin rescues SMA phenotypes in patient-derived cells and animal model.
Topics: Animals; Disease Models, Animal; Exons; Humans; Mice; Moxifloxacin; Muscular Atrophy, Spinal; Phenotype; Survival of Motor Neuron 1 Protein | 2022 |
Moxifloxacin induces aortic aneurysm and dissection by increasing osteopontin in mice.
Topics: Angiotensin II; Animals; Anti-Bacterial Agents; Aortic Aneurysm; Aortic Dissection; Disease Models, Animal; Elastin; Eosine Yellowish-(YS); Hematoxylin; Male; Matrix Metalloproteinase 2; Mice; Mice, Inbred C57BL; Moxifloxacin; Muscle Proteins; Myocytes, Smooth Muscle; Osteopontin; Rubber; Water | 2022 |
Moxifloxacin-loaded acrylic intraocular lenses: In vitro and in vivo performance.
Topics: Animals; Anti-Bacterial Agents; Aqueous Humor; Cataract Extraction; Cells, Cultured; Disease Models, Animal; Drug Delivery Systems; Endophthalmitis; Lenses, Intraocular; Moxifloxacin; Rabbits | 2019 |
Drosophila SMN2 minigene reporter model identifies moxifloxacin as a candidate therapy for SMA.
Topics: Alternative Splicing; Animals; Animals, Genetically Modified; Blood-Brain Barrier; Disease Models, Animal; Drosophila melanogaster; Drug Evaluation, Preclinical; Exons; Genes, Reporter; Humans; Moxifloxacin; Muscular Atrophy, Spinal; Survival of Motor Neuron 2 Protein | 2020 |
Efficacy of Moxifloxacin against
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Moxifloxacin; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Zebrafish | 2020 |
Efficacy of linezolid on Treponema pallidum, the syphilis agent: A preclinical study.
Topics: Animals; Area Under Curve; Clofazimine; Disease Models, Animal; Drug Evaluation, Preclinical; Linezolid; Male; Microbial Sensitivity Tests; Moxifloxacin; Penicillin G Benzathine; Rabbits; ROC Curve; Syphilis; Treponema pallidum | 2021 |
Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Levofloxacin; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Treatment Outcome | 2017 |
Efficacy of intramuscular moxifloxacin in the treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Cancellous Bone; Cortical Bone; Debridement; Disease Models, Animal; Fluoroquinolones; Histocytochemistry; Humans; Injections, Intramuscular; Male; Methicillin-Resistant Staphylococcus aureus; Moxifloxacin; Osteomyelitis; Rabbits; Staphylococcal Infections; Treatment Outcome | 2017 |
Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis, Pulmonary | 2017 |
Sensitivity and Reliability of Halothane-anaesthetized Microminipigs to Assess Risk of Drug-induced Long QT Syndrome.
Topics: Anesthetics, Inhalation; Animals; Arrhythmias, Cardiac; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoroquinolones; Halothane; Heart Rate; Long QT Syndrome; Male; Moxifloxacin; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Swine; Swine, Miniature; Terfenadine | 2017 |
Systemic Moxifloxacin in Streptococcus viridans Endophthalmitis.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Injections, Intraventricular; Moxifloxacin; Rabbits; Streptococcal Infections; Treatment Outcome; Viridans Streptococci; Vitreous Body | 2019 |
Moxifloxacin reduces Stenotrophomonas maltophilia adhesion to mouse intestinal tract in vitro.
Topics: Animals; Anti-Bacterial Agents; Bacterial Adhesion; Disease Models, Animal; Gram-Negative Bacterial Infections; Intestines; Kinetics; Male; Mice, Inbred BALB C; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Stenotrophomonas maltophilia | 2017 |
Combinations of registered drugs reduce treatment times required to deplete Wolbachia in the Litomosoides sigmodontis mouse model.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Therapy, Combination; Filariasis; Filarioidea; Fluoroquinolones; Mice; Moxifloxacin; Rifampin; Tetracyclines; Time Factors; Treatment Outcome; Wolbachia | 2018 |
Improving treatment outcome assessment in a mouse tuberculosis model.
Topics: Administration, Oral; Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Female; Genotype; Humans; Mice; Mice, Inbred BALB C; Models, Theoretical; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Treatment Outcome; Tuberculosis | 2018 |
Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Moxifloxacin; Mycobacterium tuberculosis; Recurrence; Tuberculosis, Pulmonary | 2018 |
Two-photon microscopy of fungal keratitis-affected rabbit cornea ex vivo using moxifloxacin as a labeling agent.
Topics: Animals; Aspergillosis; Candidiasis; Diagnostic Techniques, Ophthalmological; Disease Models, Animal; Eye Infections, Fungal; Imaging, Three-Dimensional; Keratitis; Microscopy, Confocal; Microscopy, Fluorescence; Moxifloxacin; Rabbits; Staining and Labeling | 2018 |
Postsurgical Cataract Prophylaxis With Intravitreal "Triamcinolone-Moxifloxacin" May Not Be Optimal For Preventing Endophthalmitis.
Topics: Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cataract Extraction; Disease Models, Animal; Drug Therapy, Combination; Endophthalmitis; Eye Infections, Bacterial; Intravitreal Injections; Male; Moxifloxacin; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Triamcinolone | 2018 |
Two-photon microscopy of Paneth cells in the small intestine of live mice.
Topics: Animals; Crohn Disease; Cytoplasmic Granules; Disease Models, Animal; Intestinal Mucosa; Intestine, Small; Mice; Mice, Inbred C57BL; Mice, Obese; Microscopy; Moxifloxacin; Paneth Cells; Photons | 2018 |
Role of moxifloxacin-dexamethasone in cardiac histomorphometric findings among Wistar rats from infected mothers.
Topics: Animals; Animals, Newborn; Dexamethasone; Disease Models, Animal; Female; Fluoroquinolones; Heart; Moxifloxacin; Myocardium; Organogenesis; Peritonitis; Pregnancy; Pregnancy Complications; Prospective Studies; Rats; Rats, Wistar | 2018 |
Development of a Broad-Spectrum Antimicrobial Combination for the Treatment of Staphylococcus aureus and Pseudomonas aeruginosa Corneal Infections.
Topics: Animals; Anti-Bacterial Agents; Cornea; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Humans; Keratitis; Mice; Mice, Inbred BALB C; Moxifloxacin; Ophthalmic Solutions; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome; Trimethoprim | 2019 |
Nanoparticle Formulation of Moxifloxacin and Intramuscular Route of Delivery Improve Antibiotic Pharmacokinetics and Treatment of Pneumonic Tularemia in a Mouse Model.
Topics: Administration, Intravenous; Animals; Anti-Bacterial Agents; Disease Models, Animal; Female; Francisella tularensis; Injections, Intramuscular; Mice; Mice, Inbred BALB C; Moxifloxacin; Nanoparticles; Pneumonia, Bacterial; Tularemia | 2019 |
Humanized Mouse Model Mimicking Pathology of Human Tuberculosis for
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Female; Granuloma; Hematopoietic Stem Cell Transplantation; Humans; Lung; Male; Mice; Mice, Inbred C57BL; Moxifloxacin; Mycobacterium tuberculosis; Tuberculosis, Pulmonary | 2019 |
Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.
Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Levofloxacin; Mice; Mice, Inbred BALB C; Moxifloxacin; Ofloxacin; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis | 2013 |
Vitreous and aqueous penetration of intravitreally and orally administered moxifloxacin in an experimental rabbit model of fungal endophthalmitis.
Topics: Animals; Antifungal Agents; Aqueous Humor; Aza Compounds; Candida albicans; Disease Models, Animal; Endophthalmitis; Eye Infections, Fungal; Fluoroquinolones; Moxifloxacin; Quinolines; Rabbits; Vitreous Body | 2013 |
Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Pyrazinamide; Random Allocation; Tuberculosis | 2015 |
Moxifloxacin is not anti-inflammatory in experimental pneumococcal pneumonia.
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Female; Fluoroquinolones; Humans; Lung; Mice, Inbred C57BL; Moxifloxacin; Pneumonia, Pneumococcal; Streptococcus pneumoniae; Treatment Outcome | 2015 |
Comparison of the Anti-angiogenic and Anti-inflammatory Effects of Two Antibiotics: Clarithromycin Versus Moxifloxacin.
Topics: Animals; Anti-Bacterial Agents; Clarithromycin; Cornea; Corneal Neovascularization; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Immunohistochemistry; Keratitis; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence; Moxifloxacin | 2016 |
Effects of Fluoroquinolone-Based Antibacterial Ophthalmic Solutions on Corneal Wound Healing.
Topics: Animals; Anti-Bacterial Agents; Cell Proliferation; Cell Survival; Corneal Injuries; Disease Models, Animal; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Levofloxacin; Moxifloxacin; Ophthalmic Solutions; Rabbits; Time Factors; Wound Healing | 2015 |
Microbiologic, Pharmacokinetic, and Clinical Effects of Corneal Collagen Cross-Linking on Experimentally Induced Pseudomonas Keratitis in Rabbits.
Topics: Animals; Anti-Bacterial Agents; Biological Availability; Collagen; Colony Count, Microbial; Cornea; Corneal Stroma; Corneal Ulcer; Cross-Linking Reagents; Disease Models, Animal; Eye Infections, Bacterial; Fluoroquinolones; Moxifloxacin; Photosensitizing Agents; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Riboflavin; Tissue Distribution | 2015 |
Efficacy of moxifloxacin & econazole against multidrug resistant (MDR) Mycobacterium tuberculosis in murine model.
Topics: Animals; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Econazole; Fluoroquinolones; Humans; Mice; Moxifloxacin; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant | 2015 |
In vivo Mycobacterium tuberculosis fluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Resistance, Bacterial; Female; Fluoroquinolones; Genotyping Techniques; Mice; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Selection, Genetic; Tuberculosis | 2016 |
Two-Photon Microscopy of the Mouse Peripheral Cornea Ex Vivo.
Topics: Animals; Collagen; Contrast Media; Cornea; Corneal Neovascularization; Disease Models, Animal; Elastin; Extracellular Matrix; Female; Fluoroquinolones; Imaging, Three-Dimensional; Limbus Corneae; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence, Multiphoton; Moxifloxacin; Sclera | 2016 |
Comparison of the effects of fourth-generation fluoroquinolones on corneal re-epithelialization in rabbit eyes.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Aza Compounds; Benzalkonium Compounds; Corneal Diseases; Disease Models, Animal; Epithelium, Corneal; Ethanol; Female; Fluoroquinolones; Gatifloxacin; Image Processing, Computer-Assisted; Male; Moxifloxacin; Ophthalmic Solutions; Preservatives, Pharmaceutical; Prospective Studies; Quinolines; Rabbits; Wound Healing | 2008 |
Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoroquinolones; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Pyrazinamide; Quinolines; Recurrence; Rifampin; Time Factors; Treatment Outcome; Tuberculosis | 2008 |
Successful treatment with moxifloxacin of experimental aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA).
Topics: Animals; Anti-Bacterial Agents; Aortic Valve; Aza Compounds; Disease Models, Animal; Endocarditis, Bacterial; Female; Fluoroquinolones; Heart Valve Diseases; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rabbits; Staphylococcal Infections; Treatment Outcome; Vancomycin | 2009 |
Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Microbial; Corneal Ulcer; Disease Models, Animal; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Ophthalmic Solutions; Quinolines; Rabbits; Staphylococcal Infections; Treatment Outcome | 2009 |
[Efficacy of levofloxacin, lomefloxacin and moxifloxacin vs. other fluoroquinolones in experimental plague due to FI+ and FI- strains of Yersinia pestis in Albino mice].
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Levofloxacin; Mice; Moxifloxacin; Ofloxacin; Plague; Quinolines; Species Specificity; Time Factors; Yersinia pestis | 2009 |
Comparison of antifungal efficacies of moxifloxacin, liposomal amphotericin B, and combination treatment in experimental Candida albicans endophthalmitis in rabbits.
Topics: Amphotericin B; Animals; Antifungal Agents; Aza Compounds; Candida albicans; Candidiasis; Colony Count, Microbial; Disease Models, Animal; Drug Resistance, Fungal; Drug Therapy, Combination; Endophthalmitis; Eye Diseases; Eye Infections, Bacterial; Eye Infections, Fungal; Fluoroquinolones; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rabbits; Vitreous Body | 2010 |
Experimental pulmonary infection and colonization of Haemophilus influenzae in emphysematous hamsters.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Bronchoalveolar Lavage Fluid; Colony Count, Microbial; Cricetinae; Disease Models, Animal; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Inflammation; Lung; Male; Moxifloxacin; Neutrophils; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Quinolines; Survival Rate; Swine; Time Factors | 2010 |
Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Microbial; Cornea; Corneal Ulcer; Disease Models, Animal; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rabbits; Specific Pathogen-Free Organisms; Staphylococcal Infections; Treatment Outcome | 2010 |
Comparative efficacy of besifloxacin and other fluoroquinolones in a prophylaxis model of penicillin-resistant Streptococcus pneumoniae rabbit endophthalmitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Microbial; Disease Models, Animal; Endophthalmitis; Fluoroquinolones; Gatifloxacin; Moxifloxacin; Ophthalmic Solutions; Penicillin Resistance; Pneumococcal Infections; Quinolines; Rabbits; Severity of Illness Index; Streptococcus pneumoniae; Time Factors | 2010 |
Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Aza Compounds; Diarylquinolines; Disease Models, Animal; Female; Fluoroquinolones; Mice; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Tuberculosis | 2010 |
Efficacy of moxifloxacin compared to teicoplanin in the treatment of implant-related chronic osteomyelitis in rats.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Chronic Disease; Disease Models, Animal; Fluoroquinolones; Injections, Intraperitoneal; Male; Moxifloxacin; Osteomyelitis; Prosthesis-Related Infections; Quinolines; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Teicoplanin; Treatment Outcome | 2010 |
Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Microbial; Corneal Ulcer; Disease Models, Animal; Disease Susceptibility; DNA, Bacterial; Drug Resistance, Bacterial; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Male; Microbial Sensitivity Tests; Moxifloxacin; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Rabbits; Sequence Analysis, DNA | 2011 |
Penetration and effectiveness of prophylactic fluoroquinolones in experimental methicillin-sensitive or methicillin-resistant Staphylococcus aureus anterior chamber infections.
Topics: Animals; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Azepines; Biological Availability; Colony-Forming Units Assay; Disease Models, Animal; Eye Infections, Bacterial; Fluoroquinolones; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rabbits; Staphylococcal Infections; Treatment Outcome | 2010 |
Moxifloxacin and cholesterol combined treatment of pneumococcal keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Cholesterol; Disease Models, Animal; Drug Therapy, Combination; Fluoroquinolones; Keratitis; Moxifloxacin; Peroxidase; Quinolines; Rabbits; Severity of Illness Index; Stem Cells; Streptococcus pneumoniae; Treatment Outcome | 2010 |
Prophylactic effect of intravenous moxifloxacin in a rabbit model of Staphylococcus epidermidis endophthalmitis.
Topics: Animals; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Injections, Intravenous; Moxifloxacin; Quinolines; Rabbits; Staphylococcal Infections; Staphylococcus epidermidis; Vancomycin | 2011 |
Torticollis in mice intravenously infected with Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Autopsy; Aza Compounds; Disease Models, Animal; Drug Therapy, Combination; Ear, Middle; Female; Fluoroquinolones; Injections, Intravenous; Isoniazid; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Otitis Media; Pyrazinamide; Quinolines; Rifampin; Torticollis; Tuberculosis | 2011 |
Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Aza Compounds; Cell Line; Disease Models, Animal; Dogs; Embryonic Stem Cells; Female; Fluoroquinolones; Heart; Heart Block; Humans; Methoxamine; Moxifloxacin; Myocytes, Cardiac; Phenethylamines; Piperidines; Potassium Channel Blockers; Pyridines; Quinolines; Rabbits; Sulfonamides; Torsades de Pointes; Ventricular Remodeling | 2012 |
Treatment of experimental Bacillus cereus endophthalmitis using intravitreal moxifloxacin with or without dexamethasone.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Bacillus cereus; Colony Count, Microbial; Dexamethasone; Disease Models, Animal; Drug Therapy, Combination; Endophthalmitis; Eye; Fluoroquinolones; Intravitreal Injections; Moxifloxacin; Quinolines; Rabbits; Time Factors; Treatment Outcome | 2011 |
Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.
Topics: Animals; Antitubercular Agents; Aza Compounds; Biological Availability; Disease Models, Animal; Drug Administration Schedule; Female; Fluoroquinolones; Granuloma; Humans; Isoniazid; Lung; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rabbits; Rifampin; Tissue Extracts; Tuberculosis, Pulmonary | 2012 |
Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions.
Topics: Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Fluoroquinolones; Gene Expression Profiling; Genes, Bacterial; Granuloma; Hypoxia; Immunohistochemistry; Male; Mice; Mice, Inbred C3H; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Positron-Emission Tomography; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis | 2012 |
Activity of sitafloxacin against extracellular and intracellular Staphylococcus aureus in vitro and in vivo: comparison with levofloxacin and moxifloxacin.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Cell Line; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose-Response Relationship, Drug; Extracellular Space; Fluoroquinolones; Intracellular Space; Levofloxacin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Peritonitis; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Time Factors | 2012 |
Anti-inflammatory effects of moxifloxacin on rat airway smooth muscle cells exposed to allergen: Inhibition of extracellular-signal-regulated kinase and nuclear factor-κB activation and of interleukin-8 and eotaxin synthesis.
Topics: Allergens; Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Asthma; Aza Compounds; Cells, Cultured; Chemokine CCL11; Dexamethasone; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Fluoroquinolones; Interleukin-8; Moxifloxacin; Myocytes, Smooth Muscle; NF-kappa B; Quinolines; Rats; Tumor Necrosis Factor-alpha | 2012 |
In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters.
Topics: Animals; Antitubercular Agents; Aza Compounds; Chronic Disease; Clofazimine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Isoniazid; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Time Factors; Tuberculosis, Pulmonary | 2012 |
Moxifloxacin as postoperative prophylaxis for Enterococcus faecalis-induced endophthalmitis after cataract surgery in aphakic rabbits.
Topics: Administration, Ophthalmic; Animals; Anti-Bacterial Agents; Aphakia, Postcataract; Aza Compounds; Disease Models, Animal; Electroretinography; Endophthalmitis; Enterococcus faecalis; Eye Infections, Bacterial; Fluoroquinolones; Gram-Positive Bacterial Infections; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Phacoemulsification; Quinolines; Rabbits; Time Factors | 2013 |
Ocular pharmacokinetics, safety and efficacy of intracameral moxifloxacin 0.5% solution in a rabbit model.
Topics: Animals; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Endophthalmitis; Epithelium, Corneal; Eye Infections, Bacterial; Fluoroquinolones; Injections, Intraocular; Microscopy, Electron, Transmission; Moxifloxacin; Phacoemulsification; Quinolines; Rabbits; Staphylococcal Infections; Streptococcal Infections; Vitreous Body | 2013 |
Experimental pneumococcal pleural empyema model: the effect of moxifloxacin.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Disease Models, Animal; Empyema, Pleural; Fluoroquinolones; Male; Moxifloxacin; Pleura; Pneumococcal Infections; Quinolines; Rabbits; Turpentine | 2003 |
Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antimalarials; Aza Compounds; Clarithromycin; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Mefloquine; Mice; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Quinolines | 2003 |
Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.
Topics: Analysis of Variance; Animals; Antitubercular Agents; Aza Compounds; Biological Availability; Culture Media; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Probability; Quinolines; Sensitivity and Specificity; Time Factors; Treatment Outcome | 2004 |
Preventive antibacterial treatment improves the general medical and neurological outcome in a mouse model of stroke.
Topics: Animals; Antibiotic Prophylaxis; Aza Compounds; Bacterial Infections; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; Escherichia coli Infections; Fever; Fluoroquinolones; Gram-Positive Bacterial Infections; Hypothermia; Immune Tolerance; Male; Mice; Mice, Inbred Strains; Moxifloxacin; Opportunistic Infections; Pneumonia, Bacterial; Quinolines; Sepsis; Stroke; Survival Rate; Treatment Outcome | 2004 |
In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome.
Topics: Administration, Oral; Animals; Aza Compounds; Blood Pressure; Chloralose; Disease Models, Animal; Dogs; Electrocardiography; Female; Fluoroquinolones; Gatifloxacin; Halothane; Heart Block; Heart Rate; Infusions, Intravenous; Long QT Syndrome; Male; Moxifloxacin; Quinolines; Rabbits; Risk Assessment; Time Factors; Torsades de Pointes; Ventricular Function, Left | 2004 |
Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice.
Topics: Abdominal Abscess; Animals; Anti-Bacterial Agents; Aza Compounds; Bacteroides fragilis; Bacteroides Infections; Clindamycin; Disease Models, Animal; Fluoroquinolones; Injections, Subcutaneous; Levofloxacin; Male; Metronidazole; Mice; Moxifloxacin; Ofloxacin; Quinolines | 2004 |
Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model.
Topics: Administration, Topical; Animals; Anterior Chamber; Aza Compounds; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Moxifloxacin; Ophthalmic Solutions; Quinolines; Rabbits; Staphylococcal Infections; Staphylococcus aureus | 2004 |
Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.
Topics: Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Moxifloxacin; Multivariate Analysis; Quinolines; Random Allocation; Reference Values; Sensitivity and Specificity; Tuberculosis, Pulmonary | 2004 |
Novel murine model of pneumococcal pneumonia: use of temperature as a measure of disease severity to compare the efficacies of moxifloxacin and levofloxacin.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Body Temperature; Colony Count, Microbial; Disease Models, Animal; Female; Fluoroquinolones; Levofloxacin; Lung; Mice; Moxifloxacin; Ofloxacin; Pneumonia, Pneumococcal; Quinolines; Skin Temperature | 2004 |
In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gemifloxacin; Levofloxacin; Mice; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Point Mutation; Quinolines; Sepsis; Streptococcus pneumoniae; Treatment Outcome | 2005 |
Treatment of Staphylococcus epidermidis endophthalmitis with intravitreal moxifloxacin in a rabbit model.
Topics: Adrenal Cortex Hormones; Animals; Anti-Infective Agents; Aza Compounds; Dexamethasone; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Inflammation; Moxifloxacin; Quinolines; Rabbits; Staphylococcal Infections; Staphylococcus epidermidis; Stem Cells; Time Factors; Vitreous Body | 2005 |
[Comparative efficiency of treatment with moxyfloxacin and lomefloxacin for generalized murine tuberculosis caused by drug-resistant Mycobacterium strains].
Topics: Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Drug Therapy, Combination; Fluoroquinolones; Liver; Lung; Mice; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Quinolones; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2005 |
The impact of mechanical ventilation on the moxifloxacin treatment of experimental pneumonia caused by Streptococcus pneumoniae.
Topics: Animals; Area Under Curve; Aza Compounds; Community-Acquired Infections; Disease Models, Animal; Fluoroquinolones; Half-Life; Male; Moxifloxacin; Pneumococcal Infections; Quinolines; Rabbits; Respiration, Artificial | 2005 |
Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model.
Topics: Animals; Anterior Chamber; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Injections; Moxifloxacin; No-Observed-Adverse-Effect Level; Ophthalmic Solutions; Quinolines; Rabbits; Safety; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome; Vancomycin; Vitreous Body | 2005 |
Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Follow-Up Studies; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary | 2005 |
Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.
Topics: Animals; Antibiotics, Antitubercular; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Follow-Up Studies; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Spleen; Treatment Outcome; Tuberculosis; Vaccines, DNA | 2005 |
QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome.
Topics: Action Potentials; Animals; Anti-Infective Agents; Area Under Curve; Arrhythmias, Cardiac; Aza Compounds; Cell Line; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Electrocardiography; Ether-A-Go-Go Potassium Channels; Female; Fluoroquinolones; Humans; Long QT Syndrome; Male; Moxifloxacin; Phenethylamines; Potassium Channels, Inwardly Rectifying; Quinolines; Rabbits; Sulfonamides; Telemetry; Treatment Outcome | 2005 |
Moxifloxacin in experimental Streptococcus pneumoniae cerebritis and meningitis.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Ceftriaxone; Disease Models, Animal; Drug Administration Schedule; Fluoroquinolones; Injections, Subcutaneous; Male; Meningitis, Pneumococcal; Mice; Mice, Inbred C57BL; Moxifloxacin; Quinolines; Treatment Outcome | 2005 |
Successful moxifloxacin prophylaxis against experimental streptococcal aortic valve endocarditis.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aortic Valve; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Endocarditis, Bacterial; Female; Fluoroquinolones; Heart Valve Diseases; Moxifloxacin; Quinolines; Rabbits; Streptococcal Infections; Streptococcus oralis | 2005 |
In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Dexamethasone; Disease Models, Animal; Female; Fluoroquinolones; Francisella tularensis; Gatifloxacin; Mice; Mice, Inbred BALB C; Moxifloxacin; Quinolines; Survival Analysis; Tularemia | 2005 |
Clindamycin and quinolone therapy for Bacillus anthracis Sterne infection in 60Co-gamma-photon-irradiated and sham-irradiated mice.
Topics: Administration, Oral; Animals; Anthrax; Anti-Bacterial Agents; Aza Compounds; Bacillus anthracis; Blood; Ciprofloxacin; Clindamycin; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Gamma Rays; Injections, Subcutaneous; Liver; Lung; Mice; Moxifloxacin; Quinolines; Radiation Injuries, Experimental; Survival Analysis | 2005 |
Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Corneal Ulcer; Disease Models, Animal; Eye Infections, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Ofloxacin; Ophthalmic Solutions; Quinolines; Rabbits | 2006 |
Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Male; Mice; Models, Biological; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae; Survival Analysis | 2006 |
The effect of treatment with moxifloxacin or azithromycin on acute bacterial rhinosinusitis in mice.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Aza Compounds; Azithromycin; CD11b Antigen; CD4 Antigens; CD8 Antigens; Disease Models, Animal; Female; Fluoroquinolones; Male; Mice; Mice, Inbred C57BL; Moxifloxacin; Pneumococcal Infections; Quinolines; Rhinitis; Sinusitis; Streptococcus pneumoniae | 2006 |
Intracameral Vigamox (moxifloxacin 0.5%) is not effective in preventing endophthalmitis in a rabbit model.
Topics: Animals; Anterior Chamber; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Injections; Moxifloxacin; No-Observed-Adverse-Effect Level; Quinolines; Rabbits; Staphylococcal Infections | 2006 |
Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model.
Topics: Animals; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Ciprofloxacin; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Rabbits; Staphylococcal Infections; Vitreous Body | 2007 |
Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
Topics: Action Potentials; Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; Dose-Response Relationship, Drug; Electrocardiography; Electrophysiologic Techniques, Cardiac; Fluoroquinolones; Heart Conduction System; In Vitro Techniques; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Rabbits; Torsades de Pointes | 2007 |
Effect of fourth-generation fluoroquinolones on the healing rate of corneal erosions in an animal model.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Corneal Diseases; Disease Models, Animal; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Male; Moxifloxacin; Quinolines; Rabbits; Wound Healing | 2007 |
Corneal wound healing in New Zealand White Rabbits following anterior keratectomy and treatment with moxifloxacin ophthalmic solution 0.5% or gatifloxacin ophthalmic solution 0.3%.
Topics: Animals; Aza Compounds; Collagen Type IV; Cornea; Disease Models, Animal; Drug Evaluation, Preclinical; Epithelium; Fluoroquinolones; Gatifloxacin; Gene Expression Profiling; Immunohistochemistry; Lasers, Excimer; Moxifloxacin; Ophthalmic Solutions; Photorefractive Keratectomy; Quinolines; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; Wound Healing | 2007 |
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Fluoroquinolones; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Secondary Prevention; Time Factors; Tuberculosis | 2007 |
Comparing the protective effects of ciprofloxacin, moxifloxacin and levofloxacin in mice with lipopolysaccharide-induced acute lung injuries.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Cytokines; Disease Models, Animal; Fluoroquinolones; Levofloxacin; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Moxifloxacin; Ofloxacin; Quinolines; Respiratory Distress Syndrome | 2008 |
Moxifloxacin versus ampicillin + gentamicin in the therapy of experimental Listeria monocytogenes meningitis.
Topics: Ampicillin; Animals; Aza Compounds; Disease Models, Animal; Drug Therapy, Combination; Fluoroquinolones; Gentamicins; Humans; Male; Meningitis, Listeria; Moxifloxacin; Quinolines; Rabbits | 2008 |
Fluoroquinolone therapy in a rabbit model of post-LASIK methicillin-resistant Staphylococcus aureus keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Corneal Stroma; Corneal Ulcer; Disease Models, Animal; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Keratomileusis, Laser In Situ; Methicillin Resistance; Moxifloxacin; Postoperative Complications; Quinolines; Rabbits; Specific Pathogen-Free Organisms; Staphylococcal Infections; Staphylococcus aureus; Surgical Flaps | 2008 |
Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis, Pulmonary | 2008 |
Ototoxicity of topical moxifloxacin in a chinchilla animal model.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Chinchilla; Cochlea; Disease Models, Animal; Evoked Potentials, Auditory, Brain Stem; Female; Fluoroquinolones; Moxifloxacin; Otitis; Quinolines | 2007 |
Comparison of rifampicin and moxifloxacin efficacy in an experimental model of animal brucellosis.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Brucellosis; Disease Models, Animal; Fluoroquinolones; Moxifloxacin; Quinolines; Rats; Rats, Wistar; Rifampin | 2008 |
Moxifloxacin in the therapy of experimental pneumococcal meningitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Fluoroquinolones; Meningitis, Pneumococcal; Moxifloxacin; Pneumococcal Infections; Quinolines; Quinolones; Rabbits; Streptococcus pneumoniae | 1998 |
[New developments in pharmacology of antibiotics].
Topics: Animals; Anti-Infective Agents; Aza Compounds; Disease Models, Animal; Drug Resistance, Microbial; Fluoroquinolones; Humans; In Vitro Techniques; Meropenem; Moxifloxacin; Quinolines; Quinolones; Thienamycins | 1998 |
Lower lipoteichoic and teichoic acid CSF concentrations during treatment of pneumococcal meningitis with non-bacteriolytic antibiotics than with ceftriaxone.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ceftriaxone; Cephalosporins; Disease Models, Animal; Fluoroquinolones; Immunoenzyme Techniques; Lipopolysaccharides; Meningitis, Pneumococcal; Moxifloxacin; Naphthyridines; Polysaccharides, Bacterial; Quinolines; Rabbits; Reference Values; Rifabutin; Teichoic Acids; Virginiamycin | 1999 |
Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Disease Models, Animal; Female; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Rabbits; Streptococcus pneumoniae | 2001 |
Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoroquinolones; Leprostatic Agents; Leprosy; Mice; Mice, Inbred Strains; Minocycline; Moxifloxacin; Probability; Quinolines; Rifampin; Treatment Outcome | 2000 |
Immunomodulatory effects of moxifloxacin in comparison to ciprofloxacin and G-CSF in a murine model of cyclophosphamide-induced leukopenia.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Bone and Bones; Bone Marrow Cells; Cell Count; Ciprofloxacin; Culture Media, Conditioned; Culture Techniques; Cyclophosphamide; Cytokines; Disease Models, Animal; Fluoroquinolones; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Granulocytes; Hematopoiesis; Hematopoietic Stem Cells; Humans; Immunity; Interleukin-6; Leukocyte Count; Leukopenia; Lung; Male; Mice; Mice, Inbred BALB C; Moxifloxacin; Quinolines; Quinolones; Spleen; Urinary Bladder | 2001 |